A Phase 1 interventional study of VLA1601 and Placebo in Zika Virus and Zika Virus Infection, sponsored by Valneva Austria GmbH. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-05.
Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Zika Virus Infection with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Zika Virus Infection · United States.
Among the 23 studies in Zika Virus Infection with a site in United States, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2018, is one of 12 in phase 1, and was the 13th registered.
78 studies on the registry are indexed under Zika Virus Infection; 8 are open to participants now.
Browse Zika Virus Infection studies →3 of the 23 studies in Zika Virus Infection with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–65 · Healthy volunteers
Cepheid · Sites in United States
Ages 14+
Children's National Research Institute · Sites in United States, Colombia
Ages 3–7 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Zika Virus Infection studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2018.
This study's enrollment of 67 is below the median of 120 across 43 interventional studies indexed under Zika Virus Infection.
Median enrollment 91 across the 16 interventional studies, 600 across the 7 observational. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Valneva Austria GmbH, one of the names counted as Valneva. Under that name alone:
Valneva Austria GmbH is the lead sponsor of 44 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Valneva has 2 studies filed under Zika Virus Infection — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Zika Virus Infection with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this Phase 1 study, two target dose levels of VLA1601, a purified, inactivated, whole Zika virus (ZIKV) vaccine candidate adsorbed on aluminum hydroxide (alum) will be evaluated: 6 antigen units (AU) and 3 AU of inactivated ZIKV vaccine. Each dose will be administered intramuscularly (i.m.) in the deltoid muscle on Days 0 and 28. In addition, an accelerated 2-dose vaccination schedule on Days 0 and 7 will be assessed for both doses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If subject is of :
i. Subject has a negative serum pregnancy test at screening (Visit 0);
ii. Subject agrees to employ adequate measures for the duration of the study. This includes one of the following measures:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
Biological: VLA1601 · Biological: Placebo
0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
Biological: VLA1601 · Biological: Placebo
0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
Biological: VLA1601 · Biological: Placebo
0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
Biological: VLA1601 · Biological: Placebo
0.5 ml Placebo on Day 0, 7 and 28
Biological: Placebo
purified inactivated ZIKV vaccine candidate adsorbed on alum
Phosphate buffered saline (PBS)
Rate of subjects with solicited adverse events including injection site and systemic reactions
Time frame: within 7 days after any vaccination
Rate of subjects with solicited adverse events including injection site and systemic reactions
Time frame: within 7 days after each vaccination
Rate of subjects with any adverse events (AEs)
Time frame: up to Day 56
Rate of subjects with any adverse events (AEs)
Time frame: during the entire study period, i.e., up to Day 208
Rate of subjects with serious adverse events (SAEs)
Time frame: up to Day 56
Rate of subjects with serious adverse events (SAEs)
Time frame: up to Day 208
Rate of subjects with any IMP-related AEs
IMP: Investigational Medicinal Product;
Time frame: up to Day 56
Rate of subjects with any IMP-related AEs
IMP: Investigational Medicinal Product;
Time frame: up to Day 208
Rate of subjects with any IMP-related SAEs
IMP: Investigational Medicinal Product;
Time frame: up to Day 56
Rate of subjects with any IMP-related SAEs
IMP: Investigational Medicinal Product;
Time frame: up to Day 208
Geometric mean titer (GMT) for ZIKV-specific neutralizing antibody titer after last active vaccination
GMT determined by plaque reduction neutralization test (PRNT)
Time frame: 7 days after last active vaccination
Geometric mean titer (GMT) for ZIKV-specific neutralizing antibody titer after last active vaccination
GMT determined by plaque reduction neutralization test (PRNT)
Time frame: 28 days after last active vaccination
GMT for ZIKV-specific neutralizing antibody titer after first vaccination
GMT determined by PRNT
Time frame: 7 days after first vaccination
GMT for ZIKV-specific neutralizing antibody titer after first vaccination
for the Day 0, 28 schedule; GMT determined by PRNT
Time frame: 28 days after first vaccination
GMT for ZIKV-specific neutralizing antibody titer after first vaccination
GMT determined by PRNT
Time frame: Day 208 after first vaccination
Rate of subjects with seroconversion after last active vaccination
Time frame: 7 days after last active vaccination
Rate of subjects with seroconversion after last active vaccination
Time frame: 28 days after last active vaccination
Rate of subjects with seroconversion after first vaccination
Time frame: 7 days after first vaccination
Rate of subjects with seroconversion after first vaccination
for the Day 0, 28 schedule
Time frame: 28 days after first vaccination
Rate of subjects with seroconversion after first vaccination
Time frame: 208 days after first vaccination
Fold increase of ZIKV-specific neutralizing antibody titers after last active vaccination as compared to baseline
Time frame: 7 after last active vaccination
Fold increase of ZIKV-specific neutralizing antibody titers after last active vaccination as compared to baseline
Time frame: 28 after last active vaccination
Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline
Time frame: 7 days after first vaccination
Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline
for the Day 0, 28 schedule
Time frame: 28 days after first vaccination
Fold increase of ZIKV-specific neutralizing antibody titers after first vaccination as compared to baseline
Time frame: 208 days after first vaccination
Ran from Feb 2018 to primary completion in Jun 2018, 4 months.
Of 21 phase 1 interventional studies under Zika Virus Infection, half reached primary completion within 15 months of starting (the median); a quarter within 8 and three quarters within 25. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.